- Report
- November 2023
- 147 Pages
Global
From €2409EUR$2,500USD£2,072GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1204EUR$1,250USD£1,036GBP
- Report
- January 2024
- 200 Pages
Global
From €3999EUR$4,150USD£3,440GBP
- Report
- August 2022
- 117 Pages
Global
From €4577EUR$4,750USD£3,937GBP
- Report
- January 2022
- 200 Pages
Global
From €7227EUR$7,500USD£6,217GBP
- Report
- January 2022
- 60 Pages
Global
From €3806EUR$3,950USD£3,274GBP
- Report
- September 2021
- 110 Pages
Global
From €4336EUR$4,500USD£3,730GBP
- Report
- January 2024
- 106 Pages
Global
From €3500EUR$3,891USD£3,116GBP
- Report
- May 2021
- 73 Pages
Global
From €3200EUR$3,557USD£2,849GBP
- Report
- February 2024
- 180 Pages
Global
From €5299EUR$5,499USD£4,558GBP
Tardive Dyskinesia (TD) is a neurological disorder characterized by involuntary, repetitive movements of the face, tongue, and extremities. It is caused by long-term use of certain medications, primarily antipsychotics, used to treat mental health disorders. As a result, the TD drug market is a subset of the Central Nervous System (CNS) drug market.
TD drugs are used to reduce the severity of TD symptoms, such as involuntary movements, and to prevent the recurrence of symptoms. These drugs are typically prescribed in combination with antipsychotics, as well as other medications, to reduce the risk of TD.
The TD drug market is highly competitive, with a number of companies offering various products. These products include both generic and branded drugs, as well as combination therapies. Companies in the TD drug market include AbbVie, Allergan, AstraZeneca, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more
